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ABSTRACT
Introduction: Among patients with acute
myeloid leukemia (AML), the DACO-016
randomized study showed reduction in
mortality for decitabine [Dacogen (DAC),
Eisai Inc., Woodcliff Lake, NJ, USA] compared
with treatment choice (TC): at primary analysis
the hazard ratio (HR) was 0.85 (95% confidence
interval 0.69–1.04; stratified log-rank
P = 0.108). With two interim analyses,
two-sided alpha was adjusted to 0.0462. With
1-year additional follow-up the HR reached 0.82
(nominal P = 0.0373). These data resulted in
approval of DAC in the European Union,
though not in the United States. Though
pre-specified, the log-rank test could be
considered not optimal to assess the observed
survival difference because of the
non-proportional hazard nature of the survival
curves.
Methods: We applied the Wilcoxon test as a
sensitivity analysis. Patients were randomized
to DAC (N = 242) or TC (N = 243).
One-hundred and eight (44.4%) patients in
the TC arm and 91 (37.6%) patients in the
DAC arm selectively crossed over to subsequent
disease modifying therapies at progression,
which might impact the survival beyond the
median with resultant converging curves (and
disproportional hazards).
Results: The stratified Wilcoxon test showed a
significant improvement in median (CI 95%)
overall survival with DAC [7.7 (6.2; 9.2)
months] versus TC [5.0 (4.3; 6.3) months;
P = 0.0458].
Conclusion: Wilcoxon test indicated
significant increase in survival for DAC versus
TC compared to log-rank test.
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INTRODUCTION
In clinical trials of end-stage or potentially fatal
diseases, survival is often the primary outcome
measure of efficacy. To get a more granular
understanding of underlying mechanisms,
survival as one component of overall
treatment efficacy is often analyzed by
comparing the survival distributions of two or
more treatment groups. There are several
potential non-parametric and parametric tests
available to compare two survival distributions.
Among non-parametric tests based on the ranks
of censored survival times, the two classic
procedures are the log-rank test and the
generalized Wilcoxon procedure. Each of these
tests has been shown to be powerful in its
ability to detect certain differences between
survival distributions [1].
Among patients with acute myeloid
leukemia (AML), the DACO-016 randomized
study (ClinicalTrials.gov identifier,
NCT00260832) showed a reduction in
mortality for decitabine [Dacogen (DAC),
Eisai Inc., Woodcliff Lake, NJ, USA] compared
with treatment choice (TC) which could be
Cytarabine or Supportive Care [2]. With the
primary analysis only showing a trend, these
data resulted in approval of DAC in the
European Union (EU), though not in the
United States (US) and, furthermore, the
French Haute Autorite´ de Sante´ negated a
mortality benefit. Though pre-specified, the
log-rank test could be considered not optimal
to assess the observed survival difference
because of the non-proportional hazard nature
of the survival curves. For testing the observed
treatment effect, Wilcoxon test is considered
more powerful compared to the log-rank test, as
the former assigns more weight to earlier events
[3]. The objective of this article was to show the
differences between the log-rank and Wilcoxon
tests for the comparison of survival
distributions in randomized controlled trials
(RCTs). We use the recent illustrative example
of decitabine in the phase III DACO-016 RCT in
patients with AML to underline the relevance of
this topic and to discuss the consequences for
designing and conducting RCTs.
METHODS
The Wilcoxon test was applied as a sensitivity
analysis by the same programmer (co-author L.
X.) using the same software (SAS, SAS Institute
Inc, NC, USA) with the same adjustments. In
the DACO-016 study, patients (aged 65 years or
older, ineligible for chemotherapy) were
randomized to DAC (N = 242) or TC
(N = 243). One-hundred and eight (44.4%)
patients in the TC arm and 91 (37.6%)
patients in the DAC arm selectively crossed
over to subsequent disease modifying therapies
at progression, which might impact the survival
beyond the median with resultant converging
curves (and disproportional hazards). Full
methodology has been described previously by
Kantarjian et al. [2].
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from all patients for being included in the study.
Adv Ther (2015) 32:854–862 855
RESULTS
The stratified Wilcoxon test showed a
significant improvement in overall survival
(OS) with DAC [7.7 (6.2; 9.2) months] versus
TC [5.0 (4.3; 6.3) months]; P = 0.0458 while at
primary analysis the stratified log-rank test
showed a non-significant improvement in OS
[hazard ratio (HR): 0.85; 95% confidence
interval (CI): 0.69–1.04; P = 0.108]. With 2
interim analyses, two-sided alpha was adjusted
to 0.0462. With one-year additional follow-up
the HR reached 0.82 (log-rank test P = 0.0373;
Wilcoxon test P = 0.0302; Table 1).
Wilcoxon test indicated significant increase
in survival already at primary analysis (CCO
2009) for DAC versus TC in patients with AML
compared to log-rank test. The overall median
survival for patients randomized to DAC
(N = 242) or TC (N = 243) was 7.7 months or
5.0 months, respectively. The overall response
rate [complete remission (CR) ? complete
remission with incomplete platelet recovery
(CRp)] was 17.8% of patients in the DAC arm
and 7.8% in the TC arm, which is statistically
significant (P = 0.001; Table 2).
As expected was the median survival for
patients who were in CR and CRp better than
for the overall population: 18.6 months for
DAC and 21.2 months for TC (P = 0.13; data
from CCO 2010).
DISCUSSION
Almost all older patients with AML have a poor
prognosis and the majority of patients are
treated with therapies that are more than
40 years old and became standard for AML in
the 1970s. In recent years a number of new
therapies, like tipifarnib (Zarnestra, Tibotec
Therapeutics, a Division of Ortho Biotech, L.P),
clofarabine (Clolar; Genzyme, Cambridge, MA,
USA), and laromustine (Onrigin; Vion
Pharmaceuticals, New Haven, CT, USA) were
tested for AML in the older population, but
failed to convince Food and Drug
Administration’s (FDA) Oncologic Drugs
Advisory Committee (ODAC) or garner
approval by the FDA or Committee for
Medicinal Products for Human Use (CHMP).
In 2012, the FDA decided to not grant approval
for DAC, a DNA methyltransferase inhibitor,
Table 1 Log-rank test versus Wilcoxon test for overall survival at CCO 2009 and 2010
Decitabine TC Decitabine vs. TC
N Death, n (%)
Median OS, months
[min; max]
N Death n (%)
Median OS, months
[min; max]
HR [95% CI] P value
CCO 2009 (protocol pre-speciﬁed)
242 197 (81.4%)
7.7 [6.2; 9.2]
243 199 (81.9%)
5.0 [4.3; 6.3]
0.85 [0.69–1.04] Log-rank test: 0.1079
Wilcoxon test: 0.0458
CCO 2010 (analysis with one-year additional follow-up)
242 219 (90.5%)
7.7 [6.2; 9.2]
243 227 (93.4%)
5.0 [4.3; 6.3]
0.82 [0.68–0.99] Log-rank test: 0.0373
Wilcoxon test: 0.0302
CCO Clinical cutoff, CI Conﬁdence interval, HR Hazard ratio, OS Overall survival, TC Treatment choice
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which is already approved by the FDA and in
over 40 countries globally for use in
myelodysplastic syndromes.
Sekeres et al. [4] discussed the shortcomings
in the development of new drugs in AML and
cited decitabine as another drug emblematic of
the ‘‘Boulevard of Broken Dreams.’’ In their
opinion, the negative decision is rooted in
rigorous statistical principles, as the primary
end point, survival difference, was not
statistically significant (P = 0.108) at the
primary analysis. An unplanned one-year
additional follow-up indicated the same
median OS while the HR reached 0.82
(nominal P = 0.037). These results, together
with significant outcomes in secondary
endpoints and a positive benefit–risk
assessment, were the basis of EMA approval of
DAC in the EU and other countries outside of
the US.
As stated by Kantarjian et al. [5], there is little
debate about the importance of rigorous
statistical principles. However, there are more
examples from clinical trials [6, 7] where the
pre-specified test, particularly for comparing
survival curves, was not the optimal choice
once the results were on the table. Since survival
curves cannot be predicted and, therefore, the
most appropriate test not always pre-specified
this need to be discussed and considered in a
better way in the future.
Comparing Time-to-Event Distributions
Time-to-event data concern elapsed time until
the occurrence of some pre-defined specific
event. In simple cases, the event is death
(survival), but also other events like
progression of a disease, recurrence of disease
(progression-free survival), or a complication
(e.g., time to first incidence of neuropathy)
might be considered. Study participants in
principle are at risk for the occurrence of the
respective event continuously over time from
the beginning of the observation [8]. However,
in RCTs the duration of observation may also
vary from one subject to another because the
subject might withdraw from the study
(e.g., due to an adverse drug reaction), the
study ends before the subject experiences that
event or due to loss of follow-up. This type of
censoring is also called ‘‘right censored’’
data since times of failure to the right are
missing.
The most established way to summarize and
compare survival data is calculating survivor
functions (or survival curves). Therefore, the
Kaplan–Meier estimate is the simplest way of
computing the survival over time despite
censoring. The Kaplan–Meier survival curve is
defined as the probability of surviving in a given
length of time while considering time in many
small intervals (e.g., day) [9].
Table 2 Median overall survival at clinical cutoff 2010 for patients with and without CR ? CRp
Decitabine TC
CR 1 CRp Total CR 1 CRp Total
No Yes No Yes
N (%) 199 (82.2) 43 (17.8) 242 224 (92.2) 19 (7.8) 243
Median survival, months 5.6 18.6a 7.7 4.4 21.2a 5.0
CR Complete remission, CRp Complete remission with incomplete platelet recovery, TC Treatment choice
a Difference is not statistically signiﬁcant
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Tests of Equality of Survivor Functions
General Procedure
The two survival curves can be compared
statistically by testing the null hypothesis, that
is, there is no difference regarding survival
between two interventions. There are several
non-parametric tests to compare two survival
distributions which are, with the exception of
the Cox test, members of a family of statistical
tests that are extensions to right censored data
of non-parametric rank tests for comparing
distributions [10]. Basically, all of these tests
follow the same procedure: at each distinct
failure time in the survival data, the
contribution to the test statistic is obtained as
a weighted standardized sum of the difference
between the observed and expected number of
deaths in each of the two groups. The expected
number of deaths is obtained under the
hypothesis of no differences between the
survivals of the two groups.
Mantel proposed the use of the procedure for
combining a series of 2 9 2 tables [10]. In this
procedure, each time, tj, a death occurs in either
group, a 2 9 2 table is formed. The entry aj
represents the observed number of deaths at
time tj in the intervention group, and cj
represents the observed number of deaths at
time tj in the control group (Table 3). Of the nj
participants at risk just prior to time tj, aj ? bj
were in the intervention group and cj ? dj were
in the control group. The expected number of
deaths in the intervention group, denoted as
E aj
 
, can be calculated as shown in Fig. 1. The
weighting factor wj, which is used for the
calculation, determines the test statistic. The
test statistics W2/V(W) has approximately a
Chi-square distribution with one degree of
freedom. If wi = 1, we obtain the
Mantel–Haenszel or log-rank test. If wi = nj/
(N ? 1), where N = the combined sample size,
we obtain the Gehan version of the Wilcoxon
test.
Thus, in simpler words, in survival analysis it
is possible to obtain different results using
different weighting factors depending on
where the survival curves separate [11]. If the
distribution of the survival curve of the study
population is known, a test with an optimal
weight function in the weighted log-rank family
might be selected before study initiation [11,
12]. However, in practice the shape is unknown
and the selection of the weights is problematic
as an inappropriate choice may result in a loss
of power [13]. However, in real-life practice a
choice is often made between versions of the
log-rank and the Gehan–Wilcoxon tests [12].
Log-Rank Test
The log-rank test, proposed by Mantel, is the
standard test used in many trials [10]. It has
been shown that the log-rank test is the best
choice for testing differences, if the so-called
proportional hazards assumption holds. This
means that the risk for an event (e.g., death) in
the intervention group is a constant multiple of
the hazard in the control group. The
assumption definitely does not hold in case
survival curves cross.
Wilcoxon Test
On the other hand, Lee et al. [14] have shown
that the Wilcoxon procedure has more power
Table 3 Procedure to calculate survival time according to
Mantel
Death at
time tj
Survivors at
time tj
At risk prior
to time tj
Intervention aj bj aj ? bj
Control cj dj cj ? dj
aj ? cj bj ? dj nj
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than the log-rank test when the HR is
non-constant (proportional hazard assumption
must be refused). As indicated above, the
Wilcoxon procedure differs from the log-rank
test only in that the deviations of observed from
expected for both groups are weighted by the
number of subjects at risk of failure at each
distinct failure time.
Thus, the Wilcoxon test is more sensitive to
differences between groups that occur at earlier
time points in the conduct of a study (more
weights to early events) whereas the log-rank
test gives equal weights to all failures regardless
to when they occur. As a result, the Wilcoxon
test is susceptible to differences in the censoring
patterns of the groups.
The HR estimate is routinely used to
empirically quantify the between-group
difference under the assumption that the ratio
of the two hazard functions is approximately
constant over time. When the underlying
proportional hazards assumption is violated
(i.e., the HR is not constant over time) the
clinical meaning of such a ratio estimate is
difficult, if not impossible, to interpret.
Selective cross-over to subsequent therapies,
which is routinely the case in oncology trials,
contributes to non-proportional hazards. In this
situation a Wilcoxon test can help to interpret
the results because it gives more weight to
earlier events when no or less subsequent
therapy was given.
The Cox proportional hazards regression
model depends on parametric assumptions.
When there is a substantial difference in
treatment effect estimates between the
covariate-adjusted and unadjusted analyses,
concerns about the proportional hazards
assumption can arise [15].
Example of Decitabine
The aforementioned differences between the
log-rank and Wilcoxon tests can be quite crucial
with regards to the interpretation of results
from clinical trials. In light of past decision by
the FDA, the RCT for decitabine (DACO-016) in
the treatment of AML is used as an illustrative
example.
The study showed a non-significant increase
in median OS with decitabine (7.7 months; 95%
CI 6.2 to 9.2) compared with TC (5.0 months;
95% CI 4.3 to 6.3): at primary analysis the HR
for OS was 0.85 (95% CI 0.69–1.04; stratified
log-rank P = 0.108). With two interim analyses,
two-sided alpha was adjusted to 0.0462. An
unplanned one-year additional follow-up
indicated the same median OS: the HR
reached 0.82 (nominal P = 0.037).
These data, together with significant
outcomes in secondary endpoints and a
Fig. 1 Procedure to calculate the expected number of
deaths in the intervention group. The expected number of
deaths in the intervention group is denoted E aj
 
. nj
participants at risk just prior to time tj, aj ? bj were in the
intervention group and cj ? dj were in the control group.
The weighting factor wj, which is used for the calculation,
determines the test statistic. The test statistics W2/
V(W) has approximately a Chi-square distribution with
one degree of freedom. If wi = 1, we obtain the
Mantel–Haenszel or log-rank test. If wi = nj/(N ? 1),
where N = the combined sample size, we obtain the
Gehan version of the Wilcoxon test
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positive benefit–risk resulted in approval of
decitabine in the EU, but not in the US.
Though pre-specified, the log-rank test could
be considered sub-optimal to assess the
observed survival difference between treatment
arms because of the non-proportional hazard
nature of the survival curves. Patients (aged
C65 years, ineligible for chemotherapy) were
randomized to decitabine (N = 242) or TC
(N = 243) but 91 (37.6%) patients in the
decitabine arm and 108 (44.4%) patients in
the TC arm selectively crossed over to
subsequent disease modifying therapies at
progression. This might have impacted the
survival beyond the median with resulting in
converging curves (and disproportional
hazards). Therefore, the Wilcoxon test was
applied as a sensitivity analysis. Naı¨ve
censoring of patients with subsequent
therapies led also like Wilcoxon to statistically
significant results when using log-rank (data not
shown).
The Wilcoxon test stratified by baseline age,
cytogenetic-risk and ECOG performance status
(an accepted classification for disease
progression) showed a significant
improvement in OS with decitabine for the
primary analysis [P = 0.0458 (and also for the
secondary analysis with one-year follow-up
(P = 0.0302)].
In this example, the Wilcoxon test indicated a
significant increase in survival for decitabine
versus TC in patients with AML compared to
results generated by applying the log-rank test in
the primary analysis. It looks like Wilcoxon test is
better than log-rank to detect the early difference
between the two Kaplan–Meier curves in this
example. These results were favorably considered
by the German Federal Joint Committee
[Gemeinsamer Bundesausschuss (G-BA)] in the
benefit assessment.
CONCLUSIONS
In general, the log-rank test and the Wilcoxon
test are actually two members of a larger class of
linear rank tests. These tests will have different
power under different circumstances. If hazards
are proportional between groups then the
log-rank test has greatest power. This fact is
approximately true for many trials and accounts
for its popularity. However, this property
sometimes does not hold; when it does not, it
is necessary to consider other tests instead, like
the Wilcoxon procedure.
Although this might be very unlikely, trials
could perhaps have been stopped earlier had the
appropriate test statistics been the pre-specified
statistic of choice [13]. In the absence of clear
indications for using the log-rank or Wilcoxon
test for the comparison of survival curves
legislators might be challenged to specify
unambiguous rules if necessary. There is a
need in the clinical community to clarify and
educate which tests are appropriate when
survival curves are non-proportional. It should
be possible to ex ante include different test
options in a statistical analysis plan making
their respective use dependent on the
proportionality of hazard rates.
In the future, an adaptively weighted
log-rank test might be appropriate because it
maintains optimality at the proportional
alternatives, while improving the power over a
wide range of non-proportional alternatives
[14]. Uno et al. [15] suggest that when there is
not sufficient information about the profile of
the between-group difference at the design
stage of the study, practitioners should
consider a pre-specified, clinically meaningful,
model-free measure for quantifying the
difference and to use robust estimation
procedures to draw primary inferences.
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